Uptake of breast cancer prevention and screening trials

D Gareth Evans (1) , Michelle Harvie (2) , Nigel Bundred (2) , Anthony Howell (3)

1 Central Manchester University foundation Trust
2 UHSM
3 The Christie

Background: Uptake of cancer trials and in particular prevention trials has been disappointing globally. Methods: We have assessed uptake to three randomized chemotherapy breast cancer prevention trials and two dietary prevention trials in women at increased familial risk and compared it with uptake of screening trials across a range of risk categories. Results: Uptake of drug prevention trials remains low at 5.3-13.6%, but is significantly higher in the high (12%) compared to very high risk group (8.4%) for IBIS1 and IBIS2 combined (p=0.004). Recruitment to two dietary prevention studies via mailshot was also disappointingly low at 6.2% and 12.5%. In contrast uptake to two mammography screening trials was >90% in all risk categories. Conclusions: More work must be done to improve recruitment to prevention trials if they are to be seen as viable alternatives to risk reducing surgery. Impact: Trial designs and decision aids need to be developed to improve recruitment.

Mots clés: Cancer: breast; Prevention; Genetic epidemiology

D Gareth Evans, Michelle Harvie, Nigel Bundred, Anthony Howell. Uptake of breast cancer prevention and screening trials. Journal of Medical Genetics, 2010, 47 (12), pp.853. ⟨10.1136/jmg.2010.082768⟩. ⟨hal-00579026⟩